AbbVie Inc (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO) announced a collaboration and option-to-license agreement to ...

Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...

This week, one Waltham biotech announced a deal to work with AbbVie that will pay out $52M upfront, while another one made ...

AbbVie has entered a partnership and option-to-license agreement with Xilio Therapeutics to develop new tumour-activated, ...

Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ocugen (OCGN – Research Report) and Xilio ...

The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...

Shares of Xilio Therapeutics Inc surged 175% on Wednesday in pre-market trading following the announcement of a collaboration and option agreement with pharmaceutical giant AbbVie (NYSE:ABBV) to ...

Xilio Therapeutics shares took flight in premarket trading Wednesday after the clinical-stage biotechnology company formed a potentially lucrative collaboration with AbbVie that includes an equity ...

NORTH CHICAGO, Ill. - Pharmaceutical (TADAWUL:2070) giant AbbVie (NYSE:ABBV), a $339 billion market cap company with a strong financial health rating according to InvestingPro, and biotech firm Xilio ...